Trinity Biotech reaches profitability inflection point, marks major milestone

Trinity Biotech (TRIB) provided a business update announcing that the Company believes it has reached a critical profitability inflection point during the latter part of the current financial quarter, a key milestone in its comprehensive transformation strategy. The Company now expects to be meaningfully Adjusted EBITDA1 -positive and to be cash flow positive from its ongoing operating activities starting Q3 2025 and into the foreseeable future. In addition, the Company today also released details regarding its results for the quarter ended March 31, 2025. Key Highlights and Developments: Trinity Biotech projects it reached Adjusted EBITDA -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its comprehensive transformation plan. The Company now expects to be meaningfully Adjusted EBITDA1 -positive and cashflow positive from ongoing operating activities, starting Q3 2025 and into the foreseeable future.